Follicular Lymphoma
Conditions
Interventions
6cycles BR treatment for patients who have refractory for 2cycles R-CHOP
Sponsors
Tatsumi Yoichi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Advanced stage Follicular lymphoma (Ann Arbor stage 3/4or stage2 with bulky) 2. Patients must have histologically determined CD20+ follicular lymphoma, grade 1-3A, with pathologic review at the participating institutions 3. Measurable disease on CT scans of at least 1.5 cm 4. Age 18-85 years 5. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 6. Adequate organ function 7.Patients without severe complications 8.Life expectancy at least 3months 9. Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
Exclusion criteria: 1.Active concurrent malignancy (except non-invasive non-melanoma skin cancer, carcinoma in situ of the cervix, or prostate intraepithelial neoplasia). If there is a history of prior malignancy, the patient must be disease-free for at least 5-years at the time of study entry. 2.Diabetes Patients who have been treated 3.Unstable or severe uncontrolled medical condition (e.g. unstable cardiac function, unstable pulmonary condition, unstable liver condition, unstable renal condition). History of tuberculosis. 4.Clinically significant cardiovascular abnormalities such as: history of stroke 5.History of interstitial pneumonia, radiation pneumonitis 6.absolute lymphoma cells in peripheral blood >25,000/microliter 7.Central nervous system lymphoma, including lymphomatous meningitis 8.History of anaphylactic shock 9.Increase the risk to the patient associated with Rituximab administration 10.Patients with severe mental disease 11.History of hematopoietic disorders 12.History of lymphoma treatment 13.Pregnant or nursing women 14.Patients with HIV positive 15.Any important medical illness or abnormal laboratory finding that would, in the investigator's judgment, increase the risk to the patient associated with his or her participation in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall response rate, CR rate, safety, prognostic factor, Overall Survival, histological transformation. | — |
Contacts
Public ContactShinya Rai
Kindai University Hospital
Outcome results
None listed